News

January 15, 2019

Volcani Center to Request Patent Coverage for Cannabis-based CTCL Therapy

News

Israel’s Volcani Center plans to submit new patent applications covering the use of a unique formulation of active compounds extracted from the cannabis plant as treatment for cutaneous T-cell lymphoma (CTCL). Further ... Read more

January 14, 2019

Burkitt’s Lymphoma/Leukemia Patients Being Recruited for CPI-613 Phase 2 Trial

News

Rafael Pharmaceuticals is currently enrolling patients with relapsed or refractory Burkitt’s lymphoma/leukemia in a Phase 2 trial to assess the potential of its lead candidate CPI-613. The study (NCT03793140) is ... Read more

January 11, 2019

Epizyme Planning to Request FDA’s Accelerated Approval of Tazemetostat for Follicular Lymphoma Patients

News

Epizyme plans to ask the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat as a treatment for people with relapsed or refractory follicular lymphoma with or without EZH2 activating mutations. ... Read more

January 10, 2019

Adcetris Not Cost-effective as Second-line Therapy for Some CTCL, U.K. Board Rules

News

The United Kingdom’s National Institute for Health and Care Excellence (NICE) concluded that Adcetris (brentuximab vedotin) is not a cost-effective option when given as a second-line therapy to people with ... Read more

January 9, 2019January 31, 2019

First-line Imbruvica-Gazyva Therapy Extends Survival Without Disease Progression in CLL/SLL Patients, Phase 3 Study Shows

News

First-line treatment with Imbruvica (ibrutinib) plus Gazyva (obinutuzumab) significantly extends the time patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) live without cancer progression, and it also increases their ... Read more

January 8, 2019

Tyvyt Approved in China for Previously Treated Classical Hodgkin’s Lymphoma

News

Tyvyt (sintilimab injection), an immune checkpoint inhibitor jointly developed by Innovent Biologics and Eli Lilly and Company in China, is now available as a therapy for patients with classical Hodgkin’s lymphoma who failed to respond ... Read more

January 7, 2019January 7, 2019

Sterile Kindergarten Uplifts Spirits of Kids With Cancer in Israel

News

This story originally appeared in the Times of Israel and is reproduced with permission. From the outside, the house in Ramat Gan, a suburb of Tel Aviv, doesn’t look all ... Read more

January 4, 2019

Calquence Shows Durable Responses in Untreated CLL/SLL Patients in Phase 1/2 Trial

News

Calquence (acalabrutinib), given as a first-line treatment to patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), showed an acceptable safety profile and reduced tumor burden in 97 percent of patients in a Phase ... Read more

January 3, 2019

Phase 3 Trial Testing Biosimilar to Rituxan, JHL1101, in DLBCL Patients Begins

News

Patient dosing has begun in a Phase 3 trial comparing JHL Biotech‘s proposed biosimilar of rituximab JHL1101 to the original medicine, Rituxan (rituximab), in diffuse large B-cell lymphoma (DLBCL), the company announced. The ... Read more

January 2, 2019

Immune Checkpoint Inhibitors Make Lymphoma Respond Better to Future Treatment, Studies Suggest

News

Patients with both Hodgkin’s and non-Hodgkin’s lymphoma who receive immune checkpoint inhibitors as their second-line or later treatment might respond better to their subsequent therapy, even if they failed to ... Read more